CureVac names a US subsidiary CEO to advance mRNA work; Sunesis shares slide after regulators nix drug app
→ Germany’s CureVac has named a US CEO to help advance its work on mRNA. And not surprisingly he’ll be based in the Boston/Cambridge hub …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
